|Bid||7.30 x 3000|
|Ask||7.40 x 1000|
|Day's Range||7.23 - 7.35|
|52 Week Range||2.02 - 7.84|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.
Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.
Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...
Shares of Pacific Biosciences of California (NASDAQ: PACB ), a developer of systems for gene sequencing, are soaring to a two-year high in pre-market trading. What Happened Pacific Biosciences announced ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
A pending buyout by Illumina overshadows the gene-sequencing company's third-quarter performance.
On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Illumina Inc. said it plans to purchase Menlo Park-based Pacific Biosciences of California Inc. for approximately $1.2 billion in a move to accelerate its scientific discovery and long-read sequencing, the company said Thursday. The all-cash transaction was set at a price of $8 per Pacific Biosciences share, with the price representing a 71 percent premium to Pacific Biosciences’ 30 trading day price, according to a statement. Illumina hopes to use the acquisition to integrate workflows and technologies "to help researchers advance their discoveries faster and clinicians offer new tests economically." “PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing,” said Francis deSouza, Illumina’s president and CEO, in the statement.
Gene sequencing company Illumina Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc in an all-cash deal valued at $1.2 billion, expanding its capabilities as the market grows. Illumina's offer of $8 per Pacific share represents a premium of about 77 percent to Pacific's Thursday close. Illumina is a major player in the nascent gene sequencing space and last year unveiled its NovaSeq sequencing platform, which is designed to deliver faster and cheaper gene sequencing over existing models.
(Reuters) - Gene sequencing company Illumina Inc (ILMN.O) said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy Pacific ...
Illumina Inc. said late Thursday that it plans to acquire Pacific Biosciences of California Inc. for $1.2 billion. Illumina stock was down less than 1% in after hours trading. Illumina said it will pay $8 per share in an all-cash deal. "[Pacific Biosciences] unmatched accuracy mirrors that of Illumina's in short-read sequencing," Illumina Chief Executive Francis deSouza said. "Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception." Goldman Sachs is serving as a financial advisor for the transaction. Illumina will hold a conference call at 5 p.m. Eastern time to discuss the transaction. Illumina stock is up 43% this year as the S&P 500 index has gained 2.5%.
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.